61
Participants
Start Date
June 26, 2023
Primary Completion Date
July 18, 2024
Study Completion Date
July 19, 2024
NNC0365-3769 (Mim8) PPX
Participants will receive Mim8 PPX once-weekly dosing (QW), once every two weeks dosing (Q2W), or once-monthly dosing s.c. injection using a prefilled fixed dose DV3407-C1 pen-injector for 26 weeks.
AKH - Klin. Abt. f. Haematologie u. Haemostaseologie, Vienna
Cliniques universitaires Saint-Luc - Service Hématologie, Brussels
Charlotte Maxeke Johannesburg Academic Hospital, Parktown, Johannesburg
Universitätsklinik für Innere Medizin V, Innsbruck
Vivantes Klinikum am Friedrichshain - Innere Medizin - Angiologie und Hämostaseologie, Berlin
Fondazione IRCSS Ca' Granda Ospedale Maggiore Policlinico, Milan
Hospital Universitario La Paz, Madrid
Hospital Regional Universitario de Málaga, Málaga
St Joseph's Children's Hospita, Tampa
Vanderbilt U Med Ctr_Nashville, Nashville
Univ Hosp Cleveland Med Ctr, Cleveland
Central Michigan University, Detroit
AOU Careggi Firenze, Florence
University of Iowa_Iowa City, Iowa City
Universitätsklinikum Bonn - Institut für Experimentelle Hämatologie, Bonn
Hospices Civils de Lyon-Hopital Cardiologique Louis Pradel-1, Bron
UC Denver Hemoph & Thrombo Ctr, Aurora
Azienda Ospedaliera di Rilievo Nazionale Santobono Pausilipon, Napoli
Children's Hospital Los Angeles - Endocrinology, Los Angeles
Penn State MS Hershey Med Ctr, Hershey
McMaster University, Hamilton
Nara Medical University Hospital_Pediatrics, Nara
Severance Hospital, Yonsei University Health System, Seoul
Gangdong Kyung Hee University Hospital, Seoul
Belfast City Hospital, Belfast
Arthur Bloom Haemophilia Centre, Cardiff
Royal Free Haemophilia Comprehensive Care Center, London
Royal Free Haemophilia Comprehensive Care Centre, London
Royal Hallamshire Hospital, Sheffield
Lead Sponsor
Novo Nordisk A/S
INDUSTRY